Literature DB >> 6602397

Expression of HLA-like structures on a permanent human tumor line PC-93.

F H Claas, G J van Steenbrugge.   

Abstract

A permanent human tumor-line PC-93 was HLA allotyped with the use of a complement-dependent cytotoxicity test supplemented with absorption experiments. In comparison with the peripheral blood lymphocytes of the patient, whose adenocarcinoma of the prostate was the origin of PC-93, remarkable differences were observed. The tumor line lacked the expression of the genetically appropriate HLA-A1, A2 and B15 antigens. Instead of these antigens, cross-reactive HLA antigens seemed to be expressed on PC-93, i.e. All, A28 and B17. Absorption experiments showed that the antibodies reactive with the neo-HLA antigens were not the same as those reactive with the specific HLA antigens. This alien expression of HLA-like structures was specific for the patients' prostatic tumor line, as EB-virus transformed B-lymphocytes of the patient expressed the genetically appropriate HLA antigens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602397     DOI: 10.1111/j.1399-0039.1983.tb00162.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  4 in total

Review 1.  The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.

Authors:  G J van Steenbrugge; M Groen; J W van Dongen; J Bolt; H van der Korput; J Trapman; M Hasenson; J Horoszewicz
Journal:  Urol Res       Date:  1989

2.  Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.

Authors:  J J König; E Kamst; A Hagemeijer; J C Romijn; J Horoszewicz; F H Schröder
Journal:  Urol Res       Date:  1989

3.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 4.  Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.

Authors:  Takeshi Namekawa; Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Cells       Date:  2019-01-20       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.